Phuong N. Huynh

Array ( [id] => 18830889 [patent_doc_number] => 20230399414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/975333 [patent_app_country] => US [patent_app_date] => 2022-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39409 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097836 [patent_doc_number] => 20240117064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/975362 [patent_app_country] => US [patent_app_date] => 2022-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18176565 [patent_doc_number] => 20230037294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => NANOPARTICLE IMMUNOCONJUGATES [patent_app_type] => utility [patent_app_number] => 17/961761 [patent_app_country] => US [patent_app_date] => 2022-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17961761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436086 [patent_doc_number] => 20230183380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS [patent_app_type] => utility [patent_app_number] => 17/960994 [patent_app_country] => US [patent_app_date] => 2022-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17960994 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449642 [patent_doc_number] => 20230190918 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => PICKERING EMULSION-BASED VACCINES [patent_app_type] => utility [patent_app_number] => 17/961147 [patent_app_country] => US [patent_app_date] => 2022-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17961147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18536151 [patent_doc_number] => 20230241239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => RETINOIC ACID MODIFIED LYSOSOME TARGETING CHIMERA MOLECULE, PREPARATION METHOD AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 17/946791 [patent_app_country] => US [patent_app_date] => 2022-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2713 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17946791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18142187 [patent_doc_number] => 20230016031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => MARROW INFILTRATING LYMPHOCYTES (MILS) AS A SOURCE OF T-CELLS FOR CHIMERIC ANTIGEN RECEPTOR (CAR) THEREAPY [patent_app_type] => utility [patent_app_number] => 17/945729 [patent_app_country] => US [patent_app_date] => 2022-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17945729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18338989 [patent_doc_number] => 20230130938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING [patent_app_type] => utility [patent_app_number] => 17/931258 [patent_app_country] => US [patent_app_date] => 2022-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 81564 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17931258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511351 [patent_doc_number] => 20230227495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => PRODUCTION OF HETERODIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 17/939736 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17939736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18227370 [patent_doc_number] => 20230066364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation [patent_app_type] => utility [patent_app_number] => 17/939109 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17939109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18176644 [patent_doc_number] => 20230037373 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => ANTI-CD38 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/823905 [patent_app_country] => US [patent_app_date] => 2022-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18272218 [patent_doc_number] => 20230093460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS [patent_app_type] => utility [patent_app_number] => 17/823496 [patent_app_country] => US [patent_app_date] => 2022-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37358 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961633 [patent_doc_number] => 12331117 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Antibody molecules which bind CD22 [patent_app_type] => utility [patent_app_number] => 17/821688 [patent_app_country] => US [patent_app_date] => 2022-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 35 [patent_no_of_words] => 56370 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18321206 [patent_doc_number] => 20230119334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => ANTIGEN RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/892089 [patent_app_country] => US [patent_app_date] => 2022-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17892089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18530011 [patent_doc_number] => 20230235079 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-27 [patent_title] => Antibody Conjugates and Methods of Making and Using the Same [patent_app_type] => utility [patent_app_number] => 17/888336 [patent_app_country] => US [patent_app_date] => 2022-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17888336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18517661 [patent_doc_number] => 11707532 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Compositions and methods of treating muscle dystrophy [patent_app_type] => utility [patent_app_number] => 17/818319 [patent_app_country] => US [patent_app_date] => 2022-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 39054 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19862317 [patent_doc_number] => 20250101103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => COMBINATIONS OF ANTIGEN BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 18/291283 [patent_app_country] => US [patent_app_date] => 2022-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 237 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18291283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077430 [patent_doc_number] => 20220403042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => THERAPEUTIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/815117 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19897883 [patent_doc_number] => 12275789 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-15 [patent_title] => Human antibodies binding to ROR2 [patent_app_type] => utility [patent_app_number] => 17/814488 [patent_app_country] => US [patent_app_date] => 2022-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 11 [patent_no_of_words] => 22336 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18306228 [patent_doc_number] => 20230110128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => USE OF ANTIBODY DRUG CONJUGATES COMPRISING TUBULIN DISRUPTING AGENTS TO TREAT SOLID TUMOR [patent_app_type] => utility [patent_app_number] => 17/870749 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17870749 [rel_patent_id] =>[rel_patent_doc_number] =>)